Dr. Todd Maderis, ND  Exploring immune dysregulation, viral reactivation, mitochondrial impairment, and treatment implications in post-EBV fatigue syndromes ...

For decades now, scientists have hypothesized that a flare-up of EBV may somehow be triggering the onset of MS. Now, a new study, led by researchers at the University of California San Francisco (UCSF ...

Ebvallo is one of a series of rare disease treatments recently turned back by the FDA amid shifting guidance that has surprised some companies and frustrated investors.

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients ...